

**FIRST**  
**INFORMATION DISCLOSURE**  
**STATEMENT BY APPLICANT**  
 (use as many sheets as necessary)

Sheet 1 of 3

Application Number	10/565,371
Filing Date	January 23, 2006
First Named Inventor	Stephane Paul
Examiner Name	
Attorney Docket No.	1032751-000123

**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)
	6,552,005	B1	BUCHSBAUM et al.	04-22-2003
	5,359,035		HABERMANN	10-25-1994

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS						
					Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Cited in Spec
	0 158 198	A1	EP	10-16-1985				X			
	0 225 579	B1	EP	06-16-1987				X			
	0 288 809	B1	EP (Corres. To USP 5,359,035)	11-02-1988				X			
	0 816 510	A1	EP	01-07-1998				X			
	94/21792	A2	WO	09-29-1994				X			
	98/40498	A2	WO	09-17-1998				X			
	99/36440	A2	WO	07-22-1999				X			
	98/08947	A1	WO	03-05-1998				X			
	93/20849	A1	WO	10-28-1993				X			
	99/60128	A1	WO	11-25-1999				X			
	02/102404	A1	WO	12-27-2002				X			
	01/93898	A1	WO	12-13-2001				X			
	03/035105	A2	WO	05-01-2003				X			
	01/68896	A1	WO	09-20-2001				X			
	01/10912	A1	WO	02-15-2001				X			
	02/101049	A2	WO	12-19-2002				X			

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	International Search Report issued in corres. PCT/EP2004/008114, March 31, 2005, EPO, Rijswijk, NL ROCK, F. et al., "Overexpression and structure - function analysis of a bioengineered IL-2/IL-6 chimeric lymphokine", Protein Engineering, September 1992, pp. 583-591, vol. 5, no. 6, Oxford University Press, Surrey, GB
	KAUFMANN, A.M., et al., "Comparison of Cytokines and CD80 for Enhancement of Immunogenicity of Cervical Cancer Cells", Immunobiology, October 2000, pp. 339-352, vol. 202, no. 4, Urban & Fischer Verlag, GERMANY
	KONDO, M., et al., "Enhancement of Interleukin-2-Induced Lymphokine-Activated Killer Activity by Interleukin 7 against Autologous Human Renal Cell Carcinoma", Oncology, November 1998, pp. 588-593, vol. 55, no. 6, S. Karger AG, Basel, SWITZERLAND

Examiner Signature	/Prema Mertz/	Date Considered	11/13/2008
--------------------	---------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

## FIRST

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/565,371
Filing Date	January 23, 2006
First Named Inventor	Stephane Paul
Examiner Name	
Attorney Docket No.	1032751-000123

Sheet 2 of 3

JU, Dian Wen, et al., "Adenovirus-mediated combined suicide gene and interleukin-2 gene therapy for the treatment of established tumor and induction of antitumor immunity", Journal of Cancer Research and Clinical Oncology, 1998, pp. 683-689, vol. 124, no. 12, Springer-Verlag, Heidelberg, GERMANY
SHANAFELT, Armen B., et al., "A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo", Nature Biotechnology, November 2000, pp. 1197-1202, vol. 18, no. 11, Nature America Inc.- http://biotech.nature.com, USA
WIGGINTON, Jon M., et al., "Synergistic Engagement of an Ineffective Endogenous Anti-Tumor Immune Response and Induction of IFN- $\gamma$ and FAS-Ligand-Dependent Tumor Eradication by Combined Administration of IL-18 and IL-2", The Journal of Immunology, October 15, 2002, pp. 4467-4474, vol. 169, no. 8, The American Association of Immunologists, Inc., Baltimore, MD
SON, Young-Ik, et al., "Interleukin-18 (IL-18) Synergizes with IL-2 to Enhance Cytotoxicity, Interferon- $\gamma$ Production, and Expansion of Natural Killer Cells", Cancer Research, February 1, 2001, pp. 884-888, vol. 61, no. 3, American Association for Cancer Research, Baltimore, MD
WANG, Q., et al., "Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma", Gene Therapy, April 2001, pp. 542-550, vol. 8, no. 7, Nature Publishing Group, London, ENGLAND
SLOS, Philippe, et al., "Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: Induction of CD8 <sup>+</sup> T-cell immunity and NK activity", Cancer Gene Therapy, 2001, pp. 321-332, Vol. 8, No. 5, Nature Publishing Group, London, ENGLAND
CAO, Renhai, et al., "Interleukin-18 acts as an angiogenesis and tumor suppressor", The FASEB Journal, December 1999, pp. 2195-2202, Vol. 13, Federation of American Societies for Experimental Biology, Bethesda, MD
MILLER, Patrice W., et al., "Intratumoral Administration of Adenoviral Interleukin 7 Gene-Modified Dendritic Cells Augments Specific Antitumor Immunity and Achieves Tumor Eradication", Human Gene Therapy, January 2000, pp. 53-65, vol. 11, Mary Ann Liebert, Inc., New York, NEW YORK
NAKANISHI, Kenji, et al., "Interleukin-18 Regulates Both TH1 and TH2 Responses", Annu. Rev. Immunol., 2001, pp. 423-474, vol. 19, Annual Reviews, Palo Alto, CA
MICALLEF, Mark J., et al., "In vivo antitumor effects of murine interferon- $\gamma$ -inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites", Cancer Immunol Immunother, 1997, pp. 361-367, vol. 43, Springer-Verlag, Heidelberg, GERMANY
OSAKI, Tadashi, et al., "IFN- $\gamma$ -Inducing Factor/IL-18 Administration Mediates IFN- $\gamma$ - and IL-12-Independent Antitumor Effects", The Journal of Immunology, 1998, pp. 1742-1749, vol. 160, The American Association of Immunologists, Baltimore, MARYLAND
OSAKI, T., et al., "Potent antitumor effects mediated by local expression of the mature form of the interferon- $\gamma$ -inducing factor, interleukin-18 (IL-18)", Gene Therapy, 1999, pp. 808-815, vol. 6, Stockton Press, United Kingdom
HASHIMOTO, Wataru, et al., "Differential Antitumor Effects of Administration of Recombinant IL-18 or Recombinant IL-12 are Mediated Primarily by Fas-Fas Ligand- and Perforin-Induced Tumor Apoptosis, Respectively", The Journal of Immunology, 1999, pp. 583-589, vol. 163, The American Association of Immunologists, Baltimore, MARYLAND
KIM, Soo-Hyun, et al., "Identification of Amino Acid Residues Critical for Biological Activity in Human Interleukin-18", The Journal of Biological Chemistry, March 29, 2002, pp. 10998-11003, Vol. 277, No. 13, The American Society for Biochemistry and Molecular Biology, Inc., Baltimore, MARYLAND
KIM, Soo-Hyun M., et al., "Site-specific mutations in the mature form of human IL-18 with enhanced biological activity and decreased neutralization by IL-18 binding protein", Proc. Natl. Acad. Sci., March 13, 2001, pp. 3304-3309, vol. 98, no. 6, USA
DANTHINNE, X., et al., "Production of first generation adenovirus vectors: a review", Gene Therapy, 2000, pp. 1707-1714, vol. 7, Macmillan Publishers Ltd., USA

Examiner Signature	/Prerna Mertz/	Date Considered	11/13/2008
--------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.M./

**FIRST**  
**INFORMATION DISCLOSURE**  
**STATEMENT BY APPLICANT**  
 (use as many sheets as necessary)

Sheet 3 of 3

Application Number	10/565,371
Filing Date	January 23, 2006
First Named Inventor	Stephane Paul
Examiner Name	
Attorney Docket No.	1032751-000123

HE, Z., et al., "Viral Recombinant Vaccines to the E6 and E7 Antigens of HPV-16", Virology, 2000, pp. 146-161, Vol. 270, Academic Press, USA

KOYAMA, Fumikazu, et al., "Combined suicide gene therapy for human colon cancer cells using adenovirus-mediated transfer of Escherichia coli cytosine deaminase gene and Escherichia coli uracil phosphoribosyltransferase gene with 5-fluorocytosine", Cancer Gene Therapy, 2000, pp. 1015-1022, Vol. 7, No. 7, Nature America, Inc., USA

Examiner Signature	/Prema Mertz/	Date Considered	11/13/2008
-----------------------	---------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P./M./